Importer of Controlled Substances Notice of Registration, 10312-10313 [2010-4770]
Download as PDF
<![CDATA[
10312
Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices
behalf of, Sharp, or any of its affiliated
companies, parents, subsidiaries,
licensees, contractors, or other related
business entities, or successors or
assigns; and (2) cease and desist orders
prohibiting Sharp Electronics Corp. and
Sharp Electronics Manufacturing Co.
from conducting any of the following
activities in the United States:
Importing, selling, marketing,
advertising, distributing, offering for
sale, transferring (except for
exportation), and soliciting U.S. agents
or distributors for, LCD devices,
including display panels and modules,
and LCD televisions or professional
displays containing the same that are
covered by claims 7 or 8 of the ‘344
patent.
On February 12, 2010, complainant
Samsung and respondent Sharp filed a
joint petition to rescind the remedial
orders under Commission Rule
210.76(a)(1) on the basis of a settlement
agreement between the parties. The
parties asserted that their settlement
agreement constitutes ‘‘changed
conditions of fact or law’’ sufficient to
justify rescission of the order under
Commission Rule 210.76(a)(1), 19 CFR
210.76(a)(1). The IA did not oppose the
joint petition.
Having reviewed the parties’
submissions, the Commission has
determined that the settlement
agreement satisfies the requirement of
Commission Rule 210.76(a)(1), 19 CFR
210.76(a)(1), that there be changed
conditions of fact or law. The
Commission therefore has issued an
order rescinding the limited exclusion
order and cease and desist orders
previously issued in this investigation.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930 (19 U.S.C. 1337) and section
210.76(a)(1) of the Commission’s Rules
of Practice and Procedure (19 CFR
210.76(a)(1)).
Issued: March 1, 2010.
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
erowe on DSK5CLS3C1PROD with NOTICES
Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 20, 2009, and
published in the Federal Register on
October 28, 2009 (74 FR 55583),
Formulation Technologies LLC., 11501
Jkt 220001
Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–4773 Filed 3–4–10; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[FR Doc. 2010–4722 Filed 3–4–10; 8:45 am]
BILLING CODE 4410–09–P
Importer of Controlled Substances
Notice of Registration
DEPARTMENT OF JUSTICE
By Notice dated October 21, 2009, and
published in the Federal Register on
October 28, 2009 (74 FR 55584), Hospira
Inc., 1776 North Centennial Drive,
McPherson, Kansas 67460–1247, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Hospira Inc. to import the basic class of
controlled substance is consistent with
the public interest, and with United
States obligations under international
Drug Enforcement Administration
By Notice dated November 23, 2009,
and published in the Federal Register
on December 2, 2009 (74 FR 63155),
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
BILLING CODE 7020–02–P
14:45 Mar 04, 2010
The company plans to import the
basic classes of controlled substances
for manufacture of active
pharmaceutical ingredients for sale to
its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Cambrex Charles City, Inc. to import the
basic classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Cambrex Charles City, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Importer of Controlled Substances
Notice of Registration
[FR Doc. 2010–4692 Filed 3–4–10; 8:45 am]
VerDate Nov<24>2008
Domain Drive, Suite 130, Austin, Texas
78758, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Fentanyl (9801), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for analytical
characterization, secondary packaging,
and for distribution to clinical trial sites.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Formulation Technologies LLC., to
import the basic class of controlled
substance is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Formulation Technologies
LLC., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Drug
Schedule
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
II
II
E:\FR\FM\05MRN1.SGM
05MRN1
Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices
10313
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Schedule
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Hospira Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances
Notice of Registration
erowe on DSK5CLS3C1PROD with NOTICES
DEPARTMENT OF JUSTICE
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 6, 2009,
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
BILLING CODE 4410–09–P
By Notice dated October 21, 2009, and
published in the Federal Register on
October 28, 2009 (74 FR 55584),
Cerilliant Corporation, 811 Paloma
Drive, Suite A, Round Rock, Texas
78665–2402, made application via the
Internet to the Drug Enforcement
Administration (DEA) to be registered as
an importer of 5-Methoxy-N,Ndiisopropyltryptamine (7439), a basic
class of controlled substance listed in
schedule I.
The company plans to import small
quantities of the listed controlled
substance for the manufacture of
analytical reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a),
and determined that the registration of
Cerilliant Corporation to import the
basic class of controlled substance is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Cerilliant Corporation to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Jkt 220001
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Application
[FR Doc. 2010–4770 Filed 3–4–10; 8:45 am]
17:26 Mar 04, 2010
[FR Doc. 2010–4771 Filed 3–4–10; 8:45 am]
Drug Enforcement Administration
Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
VerDate Nov<24>2008
Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Schedule
Tetrahydrocannabinols (7370) .....
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Etorphine HCl (9059) ...................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Metopon (9260) ............................
Dextropropoxyphene, bulk (9273)
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 4, 2010.
Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–4717 Filed 3–4–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 16, 2009, and
published in the Federal Register on
October 28, 2009, (74 FR 55586), Lonza
Riverside, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Gamma
hydroxybutyric
acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Schedule
I
II
II
The company plans to manufacture
bulk products for finished dosage units
and distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Lonza Riverside to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lonza Riverside to ensure
E:\FR\FM\05MRN1.SGM
05MRN1
]]>Agencies
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Pages 10312-10313]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-4770]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances Notice of Registration
By Notice dated October 21, 2009, and published in the Federal
Register on October 28, 2009 (74 FR 55584), Hospira Inc., 1776 North
Centennial Drive, McPherson, Kansas 67460-1247, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of Remifentanil (9739), a basic class of controlled
substance listed in schedule II.
The company plans to import Remifentanil for use in dosage form
manufacturing.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Hospira Inc. to import the basic class of controlled
substance is consistent with the public interest, and with United
States obligations under international
[[Page 10313]]
treaties, conventions, or protocols in effect on May 1, 1971, at this
time. DEA has investigated Hospira Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR
1301.34, the above named company is granted registration as an importer
of the basic class of controlled substance listed.
Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-4770 Filed 3-4-10; 8:45 am]
BILLING CODE 4410-09-P
